Trial Profile
Case-control, retrospective, single-center study assessing risk of serious bacterial infectious events (SIEs) in systemic autoimmune disease (SAID) patients treated with rituximab
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Sep 2015
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Autoimmune disorders; Systemic lupus erythematosus
- Focus Adverse reactions
- 22 Sep 2015 New trial record